Purpose: To examine and compare risks of serious hypoglycemia among antidiabetic monotherapy-treated adults receiving metformin, a sulfonylurea, a meglitinide, or a thiazolidinedione.
glimepiride, glipizide, or glyburide), meglitinide (nateglinide or repaglinide), or thiazolidinedione (TZD; pioglitazone or rosiglitazone). 2, 3 In 2012, these oral antidiabetic medications together accounted for~100 million prescriptions to over 13 million T2DM patients in the United States (US). 5 Hypoglycemia, a commonly occurring and potentially lifethreatening sequela of antidiabetic therapy, was named as 1 of 3 high-priority adverse drug events targeted by the National Action Plan for Adverse Drug Event Prevention issued in 2014 by the US Department of Health and Human Services. 6 Hypoglycemia caused by antidiabetic drugs can result in coma or seizure and is associated with latent complications including myocardial ischemic injury, dementia, and increased mortality. 7 With an increasing number of oral therapies for T2DM, the comparative safety of therapeutic alternatives is an important consideration when choosing the best therapy for a particular patient.
However, few studies have compared antidiabetic agents with respect to hypoglycemia risk, and cross-study comparisons are hindered by differences in study populations and inconsistently defined outcomes.
Randomized controlled trials in particular do not use consistent outcome definitions or necessarily reflect real-world drug effects.
Many studies treat all members of a given drug class as identical, an assumption that is seldom justified, and also neglect dose-response assessment. Moreover, serious hypoglycemia has been investigated in relatively few studies of SUs and has not been examined carefully for either meglitinides or TZDs. Recognizing this knowledge gap, the US National Action Plan for Adverse Drug Event Prevention calls for research to "identify rates of serious hypoglycemia in ambulatory care
settings" among patients receiving antidiabetic therapies. 6 We therefore examined rates of serious hypoglycemia (ie, leading to an emergency department [ED] visit or hospitalization) among individuals treated with monotherapies of metformin, an SU, a meglitinide, and a TZD.
| PATIENTS AND METHODS

| Overview and study population
We conducted a new user cohort study to examine associations between oral antidiabetic monotherapy regimens and serious hypoglycemia. The study cohort consisted exclusively of person-time exposed to monotherapy with metformin, glimepiride, glipizide, glyburide, pioglitazone, rosiglitazone, nateglinide, or repaglinide.
Users of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 agonists, or sodium-glucose co-transporter 2 inhibitors were not included. Data included enrollment and health care claims from US Medicaid enrollees aged 18 to 100 years from California, Florida, New York, Ohio, and Pennsylvania during 1999 to 2010. These states have 5 of the largest Medicaid programs in the United States, with a prevalent population of~26 million (~38% of the entire US Medicaid population). 8 Because a large proportion of Medicaid beneficiaries are co-enrolled in Medicare, 9 we also obtained and used
Medicare claims to ascertain a more complete picture of enrollees' health care.
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2.2 | Defining the study cohort
We defined apparently new users as individuals with ≥183 days of Medicaid enrollment before their first prescription for a study drug of interest; the date on which this prescription was dispensed defined cohort entry. The 183-day period immediately preceding cohort entry served as the baseline period. We did not require cohort members to meet a claims-based operational definition for T2DM during baseline or on the cohort entry date, since off-label use of these drugs would be rare, and we aimed to elucidate serious hypoglycemia risk representative of real-world use. Women with a pregnancy diagnosis during the baseline period were excluded from study. The rationale for this exclusion was to avoid areas of nonoverlap in the propensity score 13 (PS), since pregnant women treated with an SU receive glyburide almost exclusively. 14 As claims-based approaches to identifying new users are imperfect, 15 we recognized that a small proportion of subjects might actually be prevalent antidiabetic drug users. Persons could enter the cohort more than once if they re-met inclusion criteria after a censoring event (described below).
Follow-up began on cohort entry and continued until the first occurrence of the following: (1) death, as ascertained from linkage to the Social Security Administration Death Master File; (2) the 181st day; (3) >15 day gap in treatment with the study drug defining cohort entry; (4) a prescription for any other antidiabetic medication; (5) loss of Medicaid eligibility; or (6) the end of the dataset. For the proportional hazards regression analysis described below, the occurrence of an outcome of interest also served as a censoring event.
Hospitalization did not serve as a censoring event, but periods of hospitalization were excluded from follow-up time to minimize immeasurable time bias. 16 
| Ascertainment of exposure and dose
Exposure was defined by the antidiabetic drug dispensed on the day of cohort entry. Drug exposure periods were determined by: (1) (diabetes with other specified manifestations), as long as not cooccurring with ≥1 exclusionary diagnosis suggesting manifestations other than hypoglycemia (Table S3) . This algorithm, which we have used previously, [17] [18] [19] [20] has a positive predictive value of 89% for the ED component 21 and 78% for the inpatient component. 17 These performance measures were derived from validation studies within
Emergency Medicine Network data and Centers for Medicare and
Medicaid Services data, respectively, using medical records as the gold standard.
| Statistical analysis
We first calculated descriptive statistics for baseline covariates and calculated crude overall and average daily dose-stratified occurrence rates. An occurrence rate includes both incident and recurrent events, which is different from an incidence rate that only includes incident events. We then identified all T2DM patients aged 18 to 100 years with any prescription for any antidiabetic drug during 2010. This population served as the reference population for direct standardization of occurrence rates. Ninety-five percent confidence intervals (95% CIs) were calculated assuming a Poisson distribution.
Direct standardization adjusts for age and sex, but does not account for other factors related to both exposure and outcome.
We therefore used PSs to more completely adjust for confounding.
We calculated standardized mean differences for baseline covariates to examine potential differences between users of each antidiabetic drug of interest vs metformin. A standardized mean difference is the difference in means between two exposure groups divided by the pooled standard deviation. 22 A multinomial PS was generated using logistic regression. We assessed the goodness of fit of the PS model by examining the PS distribution of each antidiabetic drug of interest vs metformin. We also examined the balance between exposure groups using weighted conditional standardized differences. A weighted conditional standardized difference is the conditional difference in the mean of a covariate between two exposure groups in the units of the pooled standard deviation integrated over the distribution of the PS. 23 It allows one to compare the difference in means of baseline covariates between two exposure groups in subjects with the same PS. Lastly, we used Cox proportional hazards regression 24 to estimate hazard ratios (HRs) and 95% CIs for the associations between each study drug and the outcome, using metformin as the referent. We selected metformin as the referent because it is known to have a low risk of hypoglycemia and is commonly used. 25 Proportional hazards assumptions were examined via inclusion of an interaction term of exposure by survival time.
Two prespecified secondary analyses were performed: (1) 
| DISCUSSION
To our knowledge, this is the first study to examine and compare the rate of serious hypoglycemia among individuals receiving antidiabetic monotherapy with metformin, an SU, a meglitinide, or a TZD in a realworld setting. It is also unique as it was sufficiently powered to make meaningful comparisons among individual drugs, rather than assume that all agents of a given pharmacologic class carry the same risk.
Our study confirms that SUs are associated with higher rates of hypoglycemia than either metformin or TZDs. Bennett et al 25 Less is known about the risk of hypoglycemia associated with meglitinides. Bennett et al 25 reported a pooled odds ratio of 3.01 for meglitinides vs metformin and a statistically nonsignificant difference between SUs and meglitinides. In another meta-analysis, repaglinide was found to have a similar incidence of any hypoglycemia (ie, not limited to serious events) as SUs. 27 We found that repaglinide was associated with a rate of hypoglycemia slightly lower than that of SUs, whereas the rate for nateglinide was substantially lower and similar to metformin.
Although few studies have examined hypoglycemia among TZDs users, a prior study reported a similar risk of any hypoglycemia between TZDs and metformin. 27 We found that the rate of serious hypoglycemia in pioglitazone users was lower than that in metformin users. Although rosiglitazone had a higher standardized occurrence rate than metformin, the difference was not statistically significant after adjusting for PS. This is concordant with the finding from A Diabetes Outcome Progression Trial, 28 which found no significant difference in the number of self-reported hypoglycemic events between individuals receiving rosiglitazone and those receiving metformin. 25 The standardized occurrence rates of serious hypoglycemia reported in our study were higher than crude incidence rates reported previously both for SUs [29] [30] [31] (49.6-68.0 vs 10-30 per 1000 p-y) and metformin 32 (11.9 vs 0.6 per 1000 p-y). This is not surprising since an occurrence rate includes both initial and recurrent events. Furthermore, the follow-up period in our study was 180 days from initiation of an antidiabetic therapy, during which the risk of hypoglycemia is typically highest. In addition, our study population and the reference population used for standardization were Medicaid enrollees who have relatively high burdens of disability and chronic conditions and thus may be more vulnerable to serious hypoglycemia.
We found that the occurrence rate of serious hypoglycemia was dose dependent for all study drugs. This was not surprising for SUs and meglitinides since they stimulate insulin secretion in a dose-dependent manner. 33 Further, among patients treated with the same antidiabetic agent, those receiving higher doses usually have more serious disease and are at a higher risk of fluctuating glycemic control than those treated at lower doses. This potential confounding-by-severity among doses may be in part responsible for the observed doseresponse relationships.
Our study has a number of strengths. We avoided conflating associations between concomitant antidiabetic drugs and serious hypoglycemia by restricting the study to monotherapy-treated patients. We minimized confounding between exposure groups by using direct standardization and PS adjustment techniques and examining doseresponse relationships. We used a very large database to permit the study of less commonly used antidiabetic drugs. Finally, we used an algorithm with a high positive predictive value to identify serious hypoglycemia, thereby minimizing outcome misclassification.
Our study also has limitations. First, we probably underestimated the rate of serious hypoglycemia as defined by the American Diabetes FIGURE 1 Propensity score-adjusted hazard ratios for serious hypoglycemia, using metformin as the referent schedule and exercise. Fourth, the available sample size for nateglinide was relatively small by pharmacoepidemiologic standards, which limited our ability to generate numerically precise estimates for this drug.
Fifth, we did not study newer oral antidiabetic drugs such as dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 agonists, and sodiumglucose co-transporter 2 inhibitors. Finally, our study population consisted of Medicaid enrollees, and this may limit the generalizability of the findings. Nevertheless, because the Medicaid population is a large and vulnerable one, it is important to study.
Serious hypoglycemia caused by antidiabetic agents is widely recognized as a major clinical and public health problem and an important consideration when choosing antidiabetic therapy. Our findings support existing evidence that SUs have the highest rates of serious hypoglycemia among oral antidiabetic drugs. However, there may be clinically meaningful differences in hypoglycemia risk with different sulfonylureas.
These data may help prescribers consider serious hypoglycemia risk when choosing an oral antidiabetic agent for Medicaid beneficiaries.
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